Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • Mulligan and colleagues[Mulligan 2009] published the results of a small, open-label, proof-of-concept study using recombinant human leptin in the treatment of 8 HIV-infected patients with lipoatrophy, hypoleptinemia, insulin resistance, and dyslipidemia
    • 6 months of leptin treatment led to a significant (32%) decrease in visceral fat without significant effect on subcutaneous or peripheral fat deposits
    • Significant improvements in hepatic insulin sensitivity, serum triglyceride concentrations, and in total, LDL, and non–HDL cholesterol concentrations were also found with leptin therapy

Action required